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chromatid breakage-fusion-bridge (BFB) cycle modeland Michelle Debatisse
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hamster cell lines during amplification of the dihydrofo-Institut Pasteur
late-reductase (dhfr) and carbamyl-P-synthetase aspar-25 rue du Dr. Roux
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spectively (Smith et al., 1992; Ma et al., 1993; BertoniFrance
et al., 1994). Analyses of early amplification events have
shown that extra copies can also be acquired through
unequal segregation at mitosis of acentromeric extra-Summary
chromosomal elements bearing one or more copies of
the selected gene (Windle et al., 1991; Toledo et al.,Drug-selected intrachromosomal gene amplification
1992b, 1993), called ªdouble minutesº (DMs) (Spriggsby breakage-fusion-bridge (BFB) cycles is well doc-
et al., 1962; Cowell, 1982) or ªepisomesº (Carroll et al,umented in mammalian cells, but factors governing
1987; Maurer et al., 1987), depending on their size. Inthis mechanism are not clear. Here, we show that
the ampd2 system, early amplification by both the in-only some clastogenic drugs induce drug resistance
trachromosomal and extrachromosomal pathways canthrough intrachromosomal amplification. We strictly
occur at the same locus in cells of the same lineagecorrelate triggering of BFB cycles to induction of frag-
(Toledo et al., 1992b, 1993).ile site expression. We demonstrate a dual role for
The nature of the initial event(s) triggering either offragile sites in intrachromosomal amplification: a site
the pathways remains uncertain. It was proposed thattelomeric to the selected gene is involved in initiation,
BFB cycles may be initiated by the fusion of sister chro-while a centromeric site defines the size and organiza-
matids with shortened telomeres (Smith et al., 1990,tion of early amplified units. The positions of fragile
1992) or by a chromatid break, telomeric to the amplifiedsites relative to boundaries of amplicons found in hu-
locus (Toledo et al., 1992b, 1993; Ma et al., 1993; Kuoman cancers support the hypothesis that fragile sites
et al., 1994). In support of the first hypothesis, fusion ofplay a key role in the amplification of at least some
sister chromatids with shortened telomeres has indeed
oncogenes during tumor progression.
been observed (Hastie and Allshire, 1989; Counter et
al., 1992; Saltman et al., 1993). On the other hand, a role
Introduction for breaks in the initiation of BFB cycles is suggested
by the observation of cytological features of this mecha-
Gene amplification is a frequent manifestation of geno- nism following cell irradiation by X-ray or high linear
mic instability in cancer cells, where the amplification energy transfer particles (reviewed by Evans, 1974;
of proto-oncogenes plays a critical role in tumor pro- Moore etal, 1990; Martins et al., 1993).Chromatid breaks
gression (Bishop, 1991; Brison, 1993). Understanding have also been thought to trigger extrachromosomal
the factors triggering this phenomenon is of major clini- amplification (Windle et al., 1991). Breakage occurring
cal importance, but reconstitution of the mechanism within replication bubbles was proposed to explain the
of amplification is obscured by a variety of secondary organization of episomes as inverted repeats. In con-
rearrangements in cells recovered from advanced tu- trast, Toledo et al. (1993) obtained evidence that intrach-
mors (Nowell, 1976). The development of fluorescence romosomal looping out of DNA circles could be respon-
in situ hybridization (FISH) techniques has recently al- sible for the generation of rare DMs bearing the ampd2
lowed a comprehensive analysis of early amplification gene in cells with no cytogenetically detectable alter-
eventsat three loci in model systems of cultured hamster ation other than the frequent deletion of one chromo-
cells selected for resistance to a cytotoxic drug. These somal copy of this gene.
studies have used an experimental design whereby sec- Some clues as to the nature of the initial event(s)
ondary rearrangements, such as the well-documented responsible for amplification can be expected from the
interconversion between intrachromosomal and extra- identification and properties of agents that can induce
chromosomal units (Balaban-Mallenbaum et al., 1981; that particular mutation. Early studies on the induction
George and Powers, 1982), are limited. A major conclu- of dhfr gene amplification identified a large number of
sion drawn is that at least two different mechanisms inducers, most of which are today known to inhibit DNA
operate at the early stages. In some cases, amplification synthesis (summarized by Schimke, 1988). More recent
proceeds through an entirely intrachromosomal path- experiments have documented the induction of intrach-
way, accumulating megabase-long inverted repeats on romosomal amplification by MTX or PALA, two agents
a chromosome arm bearing the original copy of the that starve cells for DNA precursors (Rath et al., 1984;
selected gene. This was first shown by studying early Tlsty et al., 1984; Kuo et al., 1994; Poupon et al., 1996).
mutants of Chinese hamster fibroblasts that overcame Because PALA and MTX are clastogenic drugs (Li and
Kaminskas, 1984; Nelson and Kastan, 1994), their actionthe toxic action of coformycin through amplification of
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Figure 1. Breakage-Fusion-Bridge Cycles of the Chromatid Type
This model depicts the fate of a cell in which two sister chromatids bearing the selected gene have fused after replication of a broken
chromatid. At anaphase, the dicentric chromatid appears as a bridge between centromeres moving to opposite poles of the mitotic spindle.
Breakage of this giant inverted repeat leaves each daughter cell with a chromatid lacking one telomere, which again fuses after replication,
perpetuating the BFB cycles. Amplification occurs in one daughter cell when the breakage is asymmetric, leading to unequal distribution of
the selected gene in the daughter cells. The additional copies are located on the chromosome arm bearing the original copy of this gene and
are organized as megabase-long inverted repeats with one or several orders of symmetry.
is consistent with the hypothesis that breaks can trigger clastogen, while AMD induces breaks clustered at the
level of a few sites, one of which is telomeric to andamplification. The observation that out of two agents
selective for asparagine synthetase gene amplification, close to the mdr1 gene, an appropriate localization for
triggering of mdr1 amplification. These loci are specifi-the only one that is clastogenic allows the recovery
of mutants amplified for this gene also supports this cally revealed on metaphase chromosome preparations
from AMD-treated cells by a high frequency of gaps andinterpretation (Barrett and Andrulis, 1992). However,
whether the ability of agents that break DNA to stimulate breaks, a property that characterizes loci defined as
drug-sensitive ªfragile sitesº (Sutherland, 1979; Yunisamplification is general, whether the clastogenic drugs
identified as amplification inducers operate through a and Soreng, 1984; Yunis et al., 1987; Sutherland and
Richards, 1995). Remarkably, induction of intrachromo-common mechanism, and whether the same agents can
induce both BFB cycles and extrachromosomal amplifi- somal ampd2 and dhfr gene amplification was found
associated with the presence of nearby drug-activatedcation remain to be determined.
We have reevaluated here the ability of different telomeric fragile sites. Moreover, the localization of dis-
tal and proximal fragile sites bracketing the mdr1,agents to induce amplification through intrachromoso-
mal or extrachromosomal pathways. We first analyzed ampd2, and dhfr genes accounts in a simple manner
for the structural peculiarities of amplified units gener-the early stages of multi-drug resistance 1 (mdr1) gene
amplification since several different drugs can be used ated at each of these loci during the initial stages of
amplification. The results presented establish that site-to select mutants amplified for the same gene (for a
review, see Veinot and Ling, 1992). Three selective specificbreaks triggered by fragile site inducers account
for the early features of intrachromosomal amplification.agentsÐadriamycin (ADR), actinomycin D (AMD), and
vinblastin (VB)Ðwere chosen to screen for mutants of
the GMA32 Chinese hamster cell line. ADR and AMD Results
are DNA-damaging agents, known to induce p53 accu-
mulation (Fritsche et al., 1993; Nelson and Kastan, 1994), Recovery of Early Mutant Clones Resistant
to ADR, AMD, or VBwhile VB, a spindle poison, is not expected to have
clastogenic properties and does not induce p53 (Nelson To analyze independent resistant clones at a stage
allowing the unequivocal identification of the molecularand Kastan, 1994). We found that only AMD induces
mdr1 gene amplification and that only the BFB cycles amplification mechanism(s) governing multidrug resis-
tance, a protocol for the recovery of early mutants wasmechanism is significantly enhanced by this drug. We
discovered that, at the drug concentrations used to se- adapted from the method described by Smith et al.
(1990): eight cell subpopulations, small enough (50 cells)lect theamplified mutants, ADR is a powerfulbut random
BFB Cycles Triggered by Fragile Site Induction
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Table 1. Mechanism of Resistance in Independent Mutant Clones
Not Amplified
for mdr1
Amplified for mdr1
Chromosome I
Total DMs BFBs Polysomy
Selective Number of Number Number Number Number Number
Agent Analyzed Clones of Clones % of Clones % of Clones % of Clones % of Clones %
VB 37 35 94.6 2 5.4 1 2.7 1 2.7 0 0
ADR 30 25 83.3 5 16.7 1 3.3 2 6.7 2 6.7
AMD 19 6 31.6 13 68.4 0 0 10 52.6 3 15.8
to be statistically devoid of preexisting resistant mu- al., 1988) and P3C4, a telomeric marker for chromosome
1q (Toledo et al, 1992b; Figure 4B). Some clones, se-tants, were isolated and independently expanded to
lected for resistance to ADR or AMD, identified by dot5.106 cells in nonselective medium. Aliquots of cells from
blot analysis as weakly amplified, were polysomic foreach subpopulation were then independently plated in
chromosome 1 (Table 1). Since these mutants resultselective media containing ADR, AMD, or VB, each drug
from neither BFB cycles nor DM formation, they will notknown to select for mdr1 gene amplification, but only
be discussed further. Other clones exhibited a higherthe first two being clastogenic. Three concentrations of
copy number of the mdr1 gene. In some of them, theeach agent were used in parallel to adjust the selection
great majorityof cells contained DMs, frequently bearingstringencies. Seven of the initial subpopulations yielded
more than one copy of the mdr1 gene and two normala comparable small number of clones in the three drugs.
chromosomes 1, with no cytogenetically detectable al-However, the last subpopulation (designated 8) gave
teration other than the deletion of one chromosomalconfluent plates in all three drugs after 5 days, sug-
copy of the mdr1 gene (Figure 2). These observationsgesting that it contained a resistant mutant that had
appeared prior to selection. Resistant cells of subpopu-
lation 8 were pooled and analyzed by FISH. All were
diploid with unrearranged chromosomes 1 and con-
tained DMs bearing the mdr1 gene, independently of
the drug used for selection. This result suggests a clonal
origin of the resistant cells, supporting the hypothesis
that subpopulation 8 contained a preexisting mutant.
Resistant clones from the seven other subpopulations
were recovered and independently expanded in their
original selective medium for a few more generations
before analysis. We examined 37, 30, and 19 clones
resistant to VB, ADR, and AMD, respectively (Table 1).
Dot blot and cytological analyses revealed that the mdr1
gene was unamplified in some resistant mutants (not
shown). Such clones were recovered from cells selected
with AMD, ADR, or VB, and some were cross-resistant
to the three drugs. They were not further studied and the
mechanism of their resistance is unknown, but cross-
resistance most likely results from overexpression or
mutation of the mdr1 gene or of a related gene involved
in multidrug resistance (Veinot and Ling, 1992; Gottes-
man et al., 1995, 1996). The ratio of the unamplified
mutants to the total number of mutants depended strik-
ingly on the selective agent: they represented the great
majority of resistant clones that grew in the presence
of VB (94.6%) and ADR (83.3%), but the minority of those
that grew in the presence of AMD (31.6%) (Table 1).
These results identify AMD as the only potent inducer
of amplification among the three drugs tested.
Figure 2. An Example of Extrachromosomal Amplification
Top: DAPI staining; the arrows point to some DMs. Bottom: FISHMolecular Mechanisms of mdr1 Amplification
with an mdr1 probe (yellow) and a P3C4 probe, a specific markerin the Resistant Clones
of the telomeric part of chromosome 1q (red). FISH shows that theAmong the amplified clones, dot blot analysis revealed
DMs bear mdr1 copies. Consistentwith the looping-out mechanism,considerable heterogeneity in mdr1 copy number from
both chromosome 1 homologs are labeled by P3C4 spots at their
clone to clone (not shown). We screened amplified wild-type locations. Note that only one chromosome 1 bears an
clones using double color FISH with probes for the mdr1 mdr1 gene at its wild-type location (arrowhead), while the homolog
is deleted for this gene.gene (which maps at 1q26) (Sen et al., 1987; Biedler et
Cell
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distributed with comparable frequencies as products of
intrachromosomal and extrachromosomal amplification
mechanisms (Table 1). In striking contrast, all of the
highly amplified clones (10/10) recovered after selection
with AMD displayed products of BFB cycles. We consid-
ered the possibility that cells containing DMs could be
counterselected in AMD or, on the contrary, that cells
containing intrachromosomal copies of the mdr1 gene
could be counterselected in VB and ADR. Cells of sub-
population 8 (which show DMs when selected with all
three drugs) exhibited a normal growth rate inAMD when
compared to VB or ADR. Moreover, the two clones with
extrachromosomal mdr1 amplification recovered from
the other subpopulations after selection with VB or ADR
also exhibited a normal growth rate when checked for
cross-resistance toAMD. No selection against cellscon-
taining intrachromosomal copies of the mdr1 gene se-
lected in AMD was noticed during subsequent growth
in VB or ADR. Taken together, our results indicate that
AMD specifically induces the generation of mdr1 amplifi-
cation by initiating BFB cycles.
DNA Breaks Induced by the Clastogenic
Drugs ADR and AMD
To understand the striking difference in the properties
of ADR and AMD, we investigated the damages imposed
Figure 3. Examples of Structures Related to BFB Cycles
on DNA by the two drugs at the concentrations used to
FISH with mdr1 (yellow) and P3C4 (red) probes.
select mutants. As a control, we verified that no signifi-(A) An mdr1 ladder on a chromosome 1. The homolog is normal,
cant increase in DNA breaks was observed in cellswith a single copy of mdr1 and P3C4 (arrowhead) at their wild-type
treated with VB, compared to untreated cells. We foundlocations. Note the low intensity of the mdr1 single copy compared
to a rung of the ladder, suggesting that each rung bears more than that only AMD induces site-specific breaks. We focused
one mdr1 copy. on breaks on chromosome 1 and localized six major
(B) Top: DAPI staining of a sister chromatid fusion. Bottom: FISH sensitive sites (Figure 4). The main site of breakage,
showing mdr1 extracopies on fused chromatids.
expressed in 14% of mitoses and designated (a) in Fig-(C) A bridge, bearing numerous mdr1 extracopies, between in-
ure 4, was very close to and telomeric to the mdr1 gene.terphase nuclei. Note the single P3C4 (arrowhead) signal per nu-
It probably corresponds to the Chinese hamster chro-cleus, indicating that one of the two copies of this locus has been
lost; this confirmed that the BFB mechanism is operating in these mosome 1 fragile site located at 1q26±31 (Rassool et al.,
cells. 1991). In contrast, in ADR-treated cells, multiple breaks
distributed at random from cell to cell were observed
favor a looping-out mechanism for DM formation, as with no preferential location. In experiments performed
previously proposed from analysis of ampd2 gene am- with lower concentrations of ADR, giving rise to only
plification (Toledo et al., 1993). Such clones were re- few breaks per cell, no evidence for preferential break-
corded as products of extrachromosomal amplification, age sites was obtained either (not shown). The specific
although reintegration of extra copies was observed in ability of AMD to activate the expression of fragile sites,
some metaphases (not shown). Only a few clones were particularly site (a), provides an explanation for its ability
amplified by this extrachromosomal process: 1/37 in to stimulate the initiation of mdr1 intrachromosomal am-
selection with VB, 1/30 with ADR, and 0/19 with AMD plification. Moreover, the fluorescence intensity of each
(Table 1). rung of the mdr1 ladders is systematically higher than
The remaining clones exhibited intrachromosomal the fluorescence intensity of the normal locus (Figure
amplification. They contained a single copy of P3C4 on 3A), suggesting that each rung represents more than
the unamplified chromosome 1 and ladders of extra one mdr1 copy. This observation is consistent with initi-
copies of mdr1 on the other chromosome 1, the telo- ation of the process by a break close to the selected
meric part of which was deleted (Figure 3A). Occasion- gene, since each rung would then be a doublet of mdr1
ally, metaphases contained fused sister chromatids copies.
bearing the amplified mdr1 genes (Figure 3B) or an am-
plified chromatid forming a bridge between two ana-
Coformycin Induces Breaks at Fragile Sitesphase±telophase genomes (not shown). Bridges bearing
Close to the ampd2 Genethe amplified copies of mdr1 were also observed be-
Using the same cell line, we have previously selectedtween interphase nuclei containing a high level of mdr1
mutants resistant to coformycin, an adenosine analogamplification (Figure 3C). These observations show that
that acts as an inhibitor of adenylate-deaminase activity.BFB cycles operate in these clones.
No mechanism of resistance other than ampd2 geneScreening of the few highly amplified clones recov-
ered after VB or ADR selections showed that they were amplification has been detected in the large number of
BFB Cycles Triggered by Fragile Site Induction
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mutants tested and, with few exceptions, amplification
proceeded by the BFB mechanism (Toledo et al., 1992a,
1992b). The situation disclosed by the analysis of the
mdr1 system encouraged us to check for the existence
of a coformycin-activated fragile site telomeric to the
ampd2 gene. As represented in Figure 4B, coformycin
induces breaks at sites colocalized with those activated
by AMD, within the limits of precision of the mapping
technique. Among them, the (b) site, telomeric to the
ampd2 gene (Figure 4Ab), is expressed most frequently
following the coformycin challenge (13% of informative
mitoses) (Figure 4B).
Thus, the break induced at site (b) again accounts for
the triggering of amplification by BFB cycles of a gene
centromeric to this fragile site. Thefrequent coamplifica-
tion of ampd2 and P3C4 during BFB cycles (Toledo et
al., 1992b) could result from the existence of site (f),
another coformycin-inducible fragile site centromeric to
P3C4 (Figure 4Af). Indeed, induction of fragile site (f)
cannot initiate intrachromosomal ampd2 amplification
since the gene, like any marker telomeric to the break,
would be deleted. Induction of this site could instead
efficiently resolve a bridge between sister chromatids
fused at site (b) (Figure 5A). The two fragile sites flanking
the ampd2 locus would then define the size and organi-
zation of the first amplified unit. The rungs of ampd2
gene copies appear as doublets because they are sepa-
rated by twice the very short distance between ampd2
and site (b). The next cell cycle leads to formation of a
dicentric chromatid bearing two ampd2 doublets, sepa-
rated from each other by twice the distance between
ampd2 and fragile site (f). Repeated breaks at sites (f)
accumulate repeats of these large units, giving rise to
regular ladders of ampd2 doublets on the amplified
chromatid. Remarkably, the type of rearrangements pre-
dicted by this model explains entirely the generation of
the regular repeats observed early in the amplification
process, as well as the constant size of the repeats in
independent clones during the very first stages of
ampd2 amplification (Toledo et al., 1992a) (Figure 5B).
The induction of fragile site (f) is expected to stop as
soon as accumulation of a sufficiently large number of
ampd2 gene copies relieves the metabolic pressure
leading to its activation. During subsequent cell divi-
sions, BFB cycles may be perpetuated by breakage of
the bridge at random positions, leading to an increase
in the heterogeneity of the amplified units, as observed
in cells with a relatively high copy number of the ampd2
gene (Toledo et al., 1992a).
In the model just described, we considered the case
Figure 4. Breaks Induced by Coformycin or AMD at Six Major Frag- where a fragile site is broken only once. However, we
ile Sites on Chromosome 1
also considered the possibility that a fragile site remains
(A) Examples of breaks at fragile sites; arrowheads point to the
inducible after the first breakage. A secondary break atbreaks. (a): DAPI staining (top)and FISH with an mdr1 probe (bottom)
this site will only lead to a less efficient accumulationof the same metaphase, showing a break at fragile site (a) close to
of the extra copies. As an example, if an activatable siteand telomeric to the mdr1 gene. (b): FISH with an ampd2 probe
(yellow), locating fragile site (b) close to and telomeric to the ampd2 (b), remaining between the two copies of an ampd2
signal. (c±f): localization of sites (c)±(f). FISH with a P3C4 probe
identifies chromosome 1q. (e): the red arrow points to the telomeric
part of chromosome 1a containing P3C4. As previously reported
(Toledo et al., 1992), the distance between P3C4 and the telomere AMD on chromosome 1. Each red oval represents 1% of mitoses
is longer on the 1a than on the 1b homolog. (f): as in (e), one P3C4 with a break at the corresponding site. At least 250 informative
is on a normal chromosome 1b and the other is on a broken fragment mitoses were analyzed for each drug. Yellow rectangle: mdr1 gene;
of chromosome 1a. white rectangle: P3C4; black rectangle: ampd2 gene. (a)±(f) denote
(B) Localization and frequency of breaks induced by coformycin or fragile sites illustrated in (A).
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chromosome 7, telomeric to the cad gene, which could
initiate its amplification (not shown). On chromosome
2, two fragile sites telomeric to the dhfr gene could
trigger its amplification through BFB cycles, and a cen-
tromeric site could resolve the fused chromatids (Figure
6A). In this system, the two fragile sites that can initiate
the process are close together but far from the selected
gene, telomeric to the dark DAPI band specific for Chi-
nese hamster chromosome 2 (Figure 6A). This accounts
remarkably well for the large distance separating the
dhfr gene at its wild-type location from the first extra
copy (Figures 6B and 6C). FISH and banding experi-
ments showed that this large duplication is an inverted
repeat (Figure 6C). FISH with probes for the dhfr gene
and a marker close to the 2p telomere (II6) showed that
this marker is deleted on the chromosome arm bearing
dhfr ladders (not shown). These observations are com-
pletely explained by BFB cycles starting at a fragile site
telomeric to thedark DAPI band. Moreover, we observed
two slightly different types of large inverted repeats,
corresponding to the two possible initiator sites. These
were characterized by a different length of the DAPI1
band flanked by the two short symmetrical dark bands
(not shown). In most early amplifiedmutants, localization
of the third dhfr gene copy of the ladder (Figure 6C3) is
explained perfectly by a break at fragile site (ce).Figure 5. Role of Fragile Sites (b) and (f) in Early Stages of Intrachro-
mosomal ampd2 Gene Amplification
(A) A model of the role of sites (b) and (f) in ampd2 amplification.
DiscussionYellow rectangle: ampd2 gene; red arrow: fragile site (f); blue arrow:
fragile site (b); black arrowheads: telomeres; circles: centromeres;
(Br): breakage; (B1), (B2), (B3): bridges of the first, second, and third Inducers of Fragile Sites Enhance
cycles. Chromosome 1p is not drawn to scale. Gene Amplification
(B) Examples of structures formed early. FISH with a probe for the
To analyze the differential ability of clastogenic agentsampd2 gene (yellow). (1) and (2) left: normal chromosomes 1 with
to induce gene amplification, we took advantage of theampd2 at its wild-type location; right: amplified chromosomes 1
possibility to select mutants at the mdr1 locus with dif-from the same metaphases, bearing a ladder of ampd2 genes with
four (1) or three (2) regularly spaced rungs. Note that the spots at ferent drugs in cells of the same line. Both cis and trans
the level of each rung of a ladder are either split or more intense effects of the genetic background are thus avoided. In
than the spots for the single copy on the normal chromosome 1. contrast to VB, ADR and AMD are clastogenic intercalat-
ing agents. Only AMD is a potent inducer of amplifica-
tion, while VB and, surprisingly,ADR select for butdo not
doublet, is broken at stage B2, the break will lead to a induce mdr1 amplification. In the rare amplified mutants
ladder with an odd number of doublets, and may contrib- resistant to ADR or VB, the extrachromosomal and in-
ute to the formation of a ladder with three rungs (Fig- trachromosomal mechanisms appear at comparable
ure 5B2). frequencies. Strikingly, none of the amplified clones re-
covered from AMD selection exhibited extrachromo-
somal-amplified mdr1 copies. Three clones were poly-MTX Induction of Fragile Site Expression
and Gene Amplification somic for chromosome 1, and ten presented the
characteristic features of BFB cycles (Figures 3A±3C).It has been demonstrated that pretreatment with MTX
increases the frequency of mutants resistant to MTX, Thus, most, if not all, AMD-induced amplified mutants
resulted from the BFB mechanism. This property wasADR, and PALA by amplification of the dhfr, mdr1, and
cad genes, respectively (Rath et al., 1984; Tlsty et al., correlated with the ability, unique to AMD, to induce
expression of a fragile site telomeric to the mdr1 gene.1984; Kuo et al., 1994; Poupon et al., 1996). To evaluate
how general the involvement of fragile sites in the induc- The expression of fragile sites telomeric to the selected
gene was also examined at other loci, the amplificationtion of intrachromosomal amplification may be, we ex-
amined the pattern of breaks induced by MTX. of which is usually selected with clastogenic drugs
(ampd2/coformycin, dhfr/MTX). The conclusion in allWe focused on chromosome 1, which bears the mdr1
and ampd2 genes, and on chromosomes 2 and 7, which cases examined is that the drugs induce fragile sites at
locations that can trigger the amplification of the se-bear the dhfr and cad genes, respectively. Strikingly,
MTX-induced sites on chromosome 1 appear to be colo- lected genes. The redundant character of such a correla-
tion strongly supports the simple hypothesis that thesecalized with those described in Figure 4B. Among them,
sites (a) and (b), involved respectively in AMD- and cofor- drugs induce intrachromosomal amplification because
they activate the expression of fragile sites telomeric tomycin-induced amplification, were found to be also acti-
vated by MTX. Moreover, we identified a fragile site on the selected gene.
BFB Cycles Triggered by Fragile Site Induction
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Breaks induced by AMD and coformycin on chromo-
some 1 are colocalized, and most of them comap with
those revealed by the use of aphidicolin or MTX in other
studies (Rassool et al., 1991; Kuo et al., 1994), sug-
gesting that the same fragile sites are induced by these
different drugs. This offers an explanation for previous
results showing that short pretreatment of cells with
MTX increased the frequency of mutants amplified for
dhfr (Rath et al., 1984; Tlsty et al., 1984), mdr1 (Kuo et
al., 1994), and cad genes (Poupon et al., 1996). Indeed,
some of the MTX-inducible fragile sites that we mapped
on chromosomes 1, 2, and 7 are appropriately located
to trigger the amplification of the mdr1, dhfr, and cad
genes, respectively. In the CHO cell line, a possible
contribution of one of these sites to mdr1 amplification
has been proposed (Kuo et al., 1994). Pretreatment with
PALA has also been proven to increase the frequency
of amplified mutants resistant to MTX or PALA (Poupon
et al., 1996). This suggests that PALA is also able to
activate the same fragile sites as the drugs we have
studied.
Breakpoints at Telomeric and Centromeric
Fragile Sites Frame the Initial
Intrachromosomal Amplicons
We obtained striking evidence that breaks at fragile sites
control the initial steps of intrachromosomal amplifica-
tion at different loci. Because the BFB mechanism leads
to a progressive accumulation of extra copies of a gene
during clonal cell expansion, the fragile sites will remain
activated until enough copies to overcome the toxic
effects of the selective drug are acquired. Thus, the
sequential induction of two fragile sites flanking the se-
lected gene can define the size of the amplified units
and the distribution of marker genes along the amplifiedFigure 6. Role of Fragile Sites in Early Stages of Intrachromosomal
dhfr Gene Amplification array. The distance between the fragile site telomeric to
(A) Mapping of fragile sites involved in dhfr gene amplification. (n): each ampd2 and mdr1 gene is very short, and doublets
normal chromosome 2. Left: DAPI staining. The arrow shows the of these genes are observed along the initial ladders. In
large DAPI dark band specific for Chinese hamster chromosome the case of the dhfr gene, two alternative fragile sites
2p. Note that this band is telomeric to the dhfr gene. Right: FISH
initiating BFB cycles are relatively close to the telomerewith a dhfr probe (red) and an II4 probe, a marker close to and
and far from the selected gene, which readily explainstelomeric to the dhfr gene (yellow). (ce): break at fragile site centro-
the frequent occurence of very large initial inverted du-meric to the dhfr gene. Left: DAPI staining. The arrowhead shows
the break; arrow as in (n). Right: FISH with a dhfr probe (yellow). plications observed here and in previous studieson CHO
(te): break at fragile site telomeric to the dhfr gene. DAPI staining; cells (Ma et al., 1993). In all three systems examined,
symbols as in (ce). the secondary activation of a site centromeric to the
(B) A model of the role of sites (te)and (ce) in dhfr gene amplification.
gene leads to the accumulation of regular repeats (Fig-Yellow rectangle: dhfr gene; red and blue arrows: (te) and (ce) fragile
ures 5A and 6B). Chromosome translocations or dele-sites. The flash symbol points to the putative location of a break
tions with breakpoints at fragile sites are well docu-occuring during the third cycle, leading to the ladder shown in (C3).
The other features are as described in Figure 5A. Chromosome 2q mented in cultured cells (Warren et al., 1987; Glover
is not drawn to scale. and Stein, 1988). Thus, gene amplification is another
(C) Examples of amplified chromosomes. (1): DAPI (left) and FISH outcome of such site-specific breakages.
(right) with probes for the dhfr gene (red) and the II4 marker (yellow),
showing an inverted duplication. The structure with the two DAPI
dark bands (arrows) is consistent with an initial break at (te). (2):
Secondary Events in Cells Undergoing BFB Cyclestrypsin-banding of an amplified (left) and a normal (right) chromo-
some 2. The double-headed arrow shows the location of the initial When a selected gene is amplified enough, the selective
break (te). The banding pattern discloses the presence of an inverted pressure disappears and fragile site activation is likely
repeat on the amplified chromosome, probably from (te) to (ce) to stop, making the resolution of chromatid bridges de-
(black arrows). (3): DAPI (left) and FISH (right) with a probe for the pendent on random breaks that alter the initial spacing
dhfr gene (yellow) showing the large initial dhfr duplication (arrows
along the ladders. In good agreement with this hypothe-denote the two DAPI dark bands) and a third copy spaced from the
sis is the observation of a ªmixed ladderº organizationsecond by a distance consistent with a break at (ce).
in cells with a relatively high copy number of the ampd2
(Toledo et al., 1992a) or mdr1 and dhfr genes. Moreover,
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we observed bridges between anaphase±telophase nu- in determining the size and genetic content of amplified
clei, but never between interphase nuclei, of daughter units at an early stage of drug-selected amplification.
cells carrying only a few copies of the selected gene. Because the amplification of oncogenes is frequently
On the contrary, bridges like those shown in Figure 3 observed in tumor cells, it is of special interest to deter-
were observed frequently in cells with a high copy num- mine whether fragile sites are at the origin of breaks in
ber of the amplified gene, suggesting that resolution of the organism. Recently, Jacobsen Syndrome has been
the dicentromeric chromatid is delayed in these cases. related to fragile site FRA11B, the activation of which
These cytological features support the idea that at least leads to the deletion of theCBL2 proto-oncogene (Jones
two breakage mechanisms operate in sequence during et al., 1995). The hypothesis that activation of fragile
the amplification process, and that their relative utiliza- sites could be responsible for the recurrent chromo-
tion is controlled by the copy number of the selected somal rearrangements identified in some cancers was
gene. proposed more than ten years ago (Yunis, 1983; Lebeau
An expected consequence of the coexpressionof sev- and Rowley, 1984; Yunis and Soreng, 1984), and evi-
eral fragile sites in early mutants is the induction of dence that fragile site FRA3B is involved in the deletion
chromosome rearrangements. Duringamplification, ring of the FHIT tumor suppressor gene has recently been
and dicentric chromosomes are observed at a strikingly obtained (Ohta et al., 1996; Sozzi et al., 1996). Taken
high frequency from very early stages (Smith et al., together, these results suggest that fragile sites can be
1992). We discussed previously the likely role of addi- activated in vivo and can trigger targeted chromatid
tional breakage events to generate these structuresfrom breaks. To evaluate the role of fragile sites in the initia-
chromosomes undergoing BFB cycles, but the origin of tion of oncogene amplification in tumors, we consulted
such additional breaks was not explained (Toledo et al., the Genome Data Bank in an attempt to compare the
1993). The coactivation of multiple fragile sites supplies locations of fragile sites with those of oncogenes ampli-
a likely explanation for the generation of these early fied frequently in different cancers. Such an analysis is
rearrangements. necessarily limited by the fact that not all fragile sites
are localized precisely or even recorded, nor are all the
Mutants Not Induced by the Selective Agent gene maps reliable. Moreover, analysis of the amplifica-
Our study raises the question of whether additional cop-
tion process in tumor cells is obscured by secondary
ies of a gene can be acquired by the same mechanisms
rearrangements, as in advanced mutants isolated in
without induction by the selective drug. This question
vitro. We focused on the 11q13 and 12q13±14 loci, be-
has been addressed previously in thecad system,where
cause these regions contain gene clusters allowing an
it was strongly suggested that BFB cycles operate in
analysis of coamplification patterns, and amplification
both cases (Poupon et al., 1996). We show here that the
by BFB cycles is suggested in some cases by localiza-intrachromosomally amplified mutants obtained with
tion of the extra copies on the chromosome arm bearingADR and VB exhibit cytological features typical of the
the locus in normal cells (Roelofs et al., 1993; Lese etoperation of BFB cycles and that the amplified struc-
al, 1995) or by their symmetrical organization (Pedeutourtures observed in thesemutants were remarkably similar
et al., 1994). At the 11q13 locus are linked the genesto those revealed in induced mutants. Indeed, doublets
encoding the B cell CLL/lymphoma (BCL1), cyclin D1of the mdr1 gene were present in each rung of the lad-
(CCND1/PRAD1), fibroblast growth factor types 3 andders, indicating that the initiating break occurred very
4 (FGF3/INT2 and FGF4/HSTF1), the cortactin proteinclose to the selected gene. This is consistent with initia-
(EMS1), and the glycoprotein A repetition predominanttion at the same fragile site as in induced mutants, which
(GARP). These genes are frequently coamplified incould have been activated in these cases by some un-
breast, head, and neck carcinomas, in oral squamouscontrolled stress imposed on the cells.
cell carcinomas, and in other cancers (Schuuring, 1995).We also showed that the frequency of extrachromo-
This gene cluster is flanked by two fragile sites: FRA11Fsomal events is not enhanced upon selection in ADR or
(11q14.2) and FRA11A (11q13.3). Another fragile site notAMD as compared to VB. Since we verified that cells
yet precisely mapped, FRA11H (11q13) could also becontaining DMs are not strongly counterselected in the
involved in the amplification process. The 12q13±q14two clastogenic drugs, our results show that neither
region is frequently amplified in glioblastomas (Collins,AMD-induced site-specific breaks at fragile sites nor
1995) and in other cancers such as liposarcomas. Sev-ADR-induced breaks at random stimulate formation of
eral genes at this locus were coamplified frequently,DMs in this system. These observations support the
including the glioma-associated oncogene homologhypothesis that intrachromosomal and extrachromo-
(GLI), DNA damage±inducible transcript 3 (DDIT3/somal amplifications follow independent pathways (To-
GADD153), cyclin-dependent kinase 4 (CDK4), sar-ledo et al., 1993), the products of which were observed
coma-amplified sequence (SAS), and human homologat roughly similar frequencies in mutants selected with
of mouse double minute 2 (MDM2) genes. In this case,ADR or VB (Table 1). The latter result suggests that
amplification could be initiated at FRA12B (12q21.3),in model systems of drug-selected amplifications, the
and the size of the amplicon determined by FRA12Acontribution of the BFB mechanism has probably been
(12q13.1).overestimated because the agents used to select mu-
These data are consistent with the possibility thattants induce this mechanism specifically.
amplification of some oncogenes and their coamplifica-
tion patterns may depend on induction of fragile sitesFragile Sites and Gene Amplification in Tumor Cells
in vivo as well as in vitro, an hypothesis having practicalWe have demonstrated here that activation of fragile
sites plays a key role in initiating BFB cycles, as well as implications. For example, it has been proven that some
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and II4 and II6 (isolated respectively from a Chinese hamster chro-fragile sites are induced by environmental factors, such
mosome 1- and 2-specific library [M. D., B. Labidi, and P. Metezeau,as consumption of coffee or cigarette smoking (Kao-
unpublished data]) were respectively used as markers of chromo-San et al., 1987; Chen et al., 1989; Ban et al., 1995).
some 1 and 2. The probes were biotinylated by nick translation
Cigarette smoking could be involved in tumor progres- (BioNick Labeling System kit, GIBCO-BRL) or labeled with digoxi-
sion both by inducing mutations in the P53 gene (Den- genin by random priming (DIG DNA labeling kit, Boehringer).
Giemsa-trypsin Banding was performed essentially as describedissenko et al., 1996) and by triggering oncogene amplifi-
(Seabright, 1971). Briefly, slides were incubated 12 sec in trypsincation through activation of fragile sites. An elevated
0.8 mg/ml in PBS at 378C, quickly rinsed in PBS, stained 7 min inexpression of a fragile site at 11q13.3 (Kao-San et al.,
3% Giemsa (pH 6.8), and then washed in water.1987) was indeed found in cells from smokers when
compared to nonsmokers. It will be of special interest
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